Anticlonotypic monoclonal antibodies induce proliferation of clonotype- positive T cells in peripheral blood human T lymphocytes. Evidence for a phenotypic (T4/T8) heterogeneity of the clonotype-positive proliferating cells by unknown
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Monoclonal antibodies (mAb) directed to the molecular complex (formed by 
T3  molecules  and  by molecules  carrying  clonotypic  determinants)  serving  as 
receptor for antigen on human T  cells can induce cell activation, possibly leading 
to interleukin  2 (IL-2) release and cell proliferation  (1,  2).  However, although 
antibodies directed to the monomorphic T3 molecules induce polyclonal T  cell 
responses, antibodies specific for the clonotypically restricted structures (termed 
Ti) only trigger cells bearing the relevant" clonotype (3).  As a consequence, the 
functional effect(s) of anti-Ti mAb have been studied exclusively in cells belong- 
ing to the corresponding T  cell clones (used for immunization).  It is conceivable, 
however,  that  resting  peripheral  T  cells  carrying  a  given  clonotype  may  be 
susceptible  to  triggering  by  the  corresponding  anticlonotypic  antibodies  and 
undergo  proliferation.  In  this  report  we  show  that  three  mAb  (designated 
JTil_3),  originally raised against the clonotypic structure  of a  cloned variant  of 
the  IL-2-producing Jurkat leukemia cell line (designated JA3) (4,  5), and cross- 
reacting  with  0.5-1%  of peripheral  blood  (PB)  lymphocytes,  promote  (late) 
proliferation of PB T  lymphocytes. This proliferation mostly reflects the expan- 
sion of clonotype-positive (JTi  +) T  cells that express either the T4 + or the T8 + 
phenotype.  The  antibody-stimulated JTi ÷  PB  populations  express  disulphide- 
linked heterodimeric surface molecules similar to those of JA3 cells. 
Materials and  Methods 
Cells.  Mononuclear cells were isolated  from PB and, when necessary, adherent cells 
were removed by incubation on plastic  petri  dishes  (6). Purified T  lymphocytes  were 
isolated by rosetting PB lymphocytes with sheep erythrocytes as previously described (11). 
Mixed lymphocyte culture (MLC)- or phytohemagglutinin (PHA)-activated  T  cells were 
obtained as previously  described (5, 6) and further cultured in IL-2-containing  superna- 
tants for various periods of time before fluorescence-activated  cell sorter (FACS) analysis. 
The 6-thioguanine-resistant  JA3 cloned cell line was selected, as previously described (4). 
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mAb, Immunofluorescence Staining,  and FACS Analysis.  JTil_3  mAb were obtained by 
immunizing mice  with  cells  from  a  cloned  variant  of the Jurkat  leukemic  T  cell  line 
(termed JA3) (surface phenotype: T11 ÷, T3 ÷,  3A1 +, T6-,  T4-,  T8-,  HLA-DR-, Tac-, 
4F2 ÷) (4).  They were shown to recognize clonotypically restricted,  heterodimeric  struc- 
tures of JA3 cells (4). JA3 produced large amounts of IL-2 upon stimulation with PHA 
(anti-T3 or anti-JTi antibodies) in conjunction with phorbol myristate acetate (PMA) or 
adherent cells (5).  The  UCHT-1  (anti-T3),  B9-4 (anti-T8),  Dl-12 (anti-HLA-DR), anti- 
Tac,  and  the  4F2  mAb  were  generous  gifts  of  Drs.  Crumpton,  Malissen,  Accolla, 
Waldmann, and Fauci (5). The OKT4A mAb was purchased from Ortho Pharmaceutical 
Corp., (Raritan,  N  J). The anti-Leu-1  mAb was purchased from Becton-Dickinson, Basel, 
Switzerland.  The techniques  used for staining cells by immunofluorescence,  for  FACS 
analysis and for cell sorting, have been described in detail (6). 
Characterization of Radioiodinated  Cell Surface Proteins.  ~107 JA3 cells  or anti-JTi2- 
stimulated  lymphocytes (7  d  plus  3  d  in Ab-free media)  were surface labeled  with  125I 
using lactoperoxidase-glucose-oxidase-catalyzed iodination,  and were lysed as described 
(7). The material  immunoprecipitated by anti-JTi2 mAb was analyzed on  11% (reduced) 
or 8%  (nonreduced) discontinuous sodium dodecyl sulfate (SDS)-polyacrylamide gels as 
described (4, 7). 
Stimulation ofPB Lymphocytes with mAb.  Purified T  lymphocytes (or unfractionated PB 
mononuclear cells)  were cultured in round-bottomed microwells (105 cells per well) with 
one or another  mAb in RPMI  1640 culture medium supplemented  with  10%  fetal calf 
serum  (5).  Anti-JTi  mAb were used at a  1:100 final dilution  of the hybridoma culture 
supernatant (or, in some experiments, at a  1:5000 dilution of the ascitic fluid). UCHT-1 
was used at a  1:5000 dilution of the ascitic fluid, whereas the anti-Leu-I mAb was used at 
a  1:500 dilution  of the  stock solution.  Cultures  were continued for different intervals, 
and  0.5  #Ci  of tritiated  thymidine  ([3H]TdR)  was  added  18  h  before  collection  and 
measurement of TdR uptake (5). 
Results  and  Discussion 
As previously shown (4,  5), anti-JTi~_3 antibodies  react strongly with JA3 cells 
but they do not appear to bind  to PB resting or activated T  cells as assessed by 
indirect  immunofluorescence  and  FACS  analysis.  However,  by  fluorescence 
microscope examination,  0.5-1% of cells were found to beJTi + in three different 
individuals.  When  PB lymphocytes were cultured  in the presence of any one of 
the anti-JTi mAb, a detectable proliferation started at day 5 and reached maximal 
levels  at  day  7-9  (Fig.  1).  No  proliferation  was  detected  in  control  cultures 
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FIGURE  1.  Anticlonotypic  antibodies  induce  (late) proliferative  responses  of PB  human 
mononuclear cell populations.  Ficoll/Hypaque-purified  mononuclear cells were cultured in 
round-bottomed microwells (105 cells per well) with either one of the following mAb: anti- 
JTi~ (A), anti-Leu-1  (['-I), UCHT1  (@). Cultures  were continued for various periods  of time 
before scoring for [3H]TdR uptake. MORETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT  1395 
containing other mAb of the same IgG2A subclass, such as 4F2 (not shown) or 
Leu-1  (Fig.  1).  Similar results were obtained in  20  different individuals: in all 
instances a measurable cell proliferation began at day 5-6 and peaked at day 7- 
9.  Polyclonal stimulation  of the  same cell  populations  with  anti-T3  antibody 
resulted  in  a  strong proliferative response  as  early as at  day 2-3  of culture. 
Removal of adherent cells abrogated proliferative responses of PB lymphocytes 
to  both  anti-JTi  and  anti-T3  mAb (data  not  shown).  To  assess  whether cell 
proliferation reflected, at least in part, the clonal expansion of cells carrying the 
JTi clonotype (or crossreacting clonotypes), lymphocytes cultured for 7 d  with 
anti-JTi2 mAb were harvested, washed extensively, and further kept in antibody- 
free medium for 48 h before staining with anti-JTi or anti-T3 mAb and analysis 
by FACS.  The  rationale  for this  experimental procedure was  that  antibodies 
directed to the T3/Ti receptor complex are known to induce a reversible loss of 
these antigens from the cell surface ("modulation") (1). >90% of the large (blast) 
ceils were found to be T3+; more importantly, 70-90% expressed JTi determi- 
nants (see Fig. 2). Time course experiments showed that, while virtually no JTi  + 
cells were detectable at day 0, few positive cells were present after a total culture 
period of 4 d and that they represented ~20% of the cells at day 6. At day 10, 
as much as 40%  of the total cells recovered were JTi  + (not shown). Moreover, 
similar proportions ofJTi  + cells, after stimulation with anti-JTiz mAb, could be 
detected with any of the anti-JTi mAb, including the anti-JTil mAb that recog- 
nizes on theJA3 T  cell receptor an epitope distinct from that recognized by anti- 
JTi2 or anti-JTi3 mAb (4) (not shown). On the other hand, in control experiments 
in which cells were stimulated with anti-T3 mAb or cultured in the presence of 
PHA or allogeneic cells, <1% JTi  + cells were detectable after 4-15 d of culture. 
The increase in the proportion ofJTi  ÷ cells was paralleled by the expression of 
T  cell  activation  markers  such  as  HLA-DR,  the  receptor for  IL-2  and  4F2 
antigens. Thus, for example, after 8 d of culture, 38% of the cells were stained 
by anti-JTi2  mAb, whereas 38,  42,  and 45%  were HLA-DR  +,  IL-2  receptor- 
positive, or 4F2 +, respectively, as assessed by specific mAb and FACS analysis. 
In addition, these antigens appeared to be expressed by the same large cells that 
expressed JTi  determinants.  In  some  experiments, JTi  +  blasts  were  further 
purified by FACS and cultured for an additional 3 d  in IL-2-containing super- 
natant (6). Cells were then analyzed for expression of  JTi determinants and also 
for T4  and T8  subset-specific surface antigens:  Virtually  100%  of the sorted 
cells expressed T3 andJTi determinants (Fig. 2, D and E) whereas approximately 
55 and 40% were T4 ÷ and T8 +, respectively; >90% of cells were positive when 
stained simultaneously with anti-T8 and anti-T4 mAb, indicating that the cor- 
responding antigens were expressed by different cells (Fig. 2 F). 
Next,  we  compared  the  anti-JTi-reactive  molecules in  T  cell  populations 
stimulated for 7  d  with anti-JTiz mAb (and cultured for 72 h  in antibody-free 
media) with those expressed on JA3 leukemia cells. Cells were surface labeled 
with  ~25I  by  the  lactoperoxidase-glucose-oxidase-catalyzed iodination  method 
(7).  They were then  lysed and the resulting cell extracts immunoprecipitated 
with anti-JTi2.  Upon SDS-polyacrylamide gel electrophoresis (PAGE), the mol- 
ecules recognized by anti-JTi2  in  both  lysates displayed an Mr of ~85,000  in 
nonreducing conditions.  Under reducing conditions, the Mr 85,000  band  was 1396  MORETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 2.  Phenotypic heterogeneity of PB-derived JTi ÷ cells. JTi ÷ ceils were isolated by 
FACS sorting from PB mononuclear cells that had been cultured for 12 d with anti-JTi2 mAb. 
After sorting and  extensive washing, cells were  cultured  for  3  d  in  antibody-free media 
containing exogenous IL-2 and then stained with one or another of the following mAb: anti- 
T3 (A), anti-JTie (B), anti-T4 (D), anti-T8 (E). In C control cells were stained with the second 
reagent only. (F) Cells were stained simultaneously with anti-T4 and anti-T8 mAb. Positive 
cells were >90%, indicating that T4 and T8 antigens were expressed by different ceils. 
resolved in  bands of approximately 40,000,  45,000,  and 49,000  (Fig.  3).  The 
presence of a  third  band  in  anti-JTi  immunoprecipitates from Jurkat-derived 
clones is in line with previous data from our own and others' laboratories (4, 5). 
We therefore conclude that molecules carrying clonotypic determinants in JA3 
cells  and  in  lymphocyte populations  stimulated  with  anti-JTi  antibodies  are 
similar. 
Taken together, the present results indicate that antibodies directed to clon- 
otypic  structures  (or  recognizing  framework  determinants  present  on  small 
subsets of T  cell receptors) can induce extensive proliferation of the few clono- 
type-positive T  cells present in normal T  cell populations. Similar data have been 
recently reported by Bigler et al. (8) using the $511  mAb, which recognizes the 
human T  cell antigen receptor expressed by a T  cell leukemia and by 1-2%  of 
peripheral T  cell. Whether any anticlonotypic antibody may behave in a similar 
fashion remains to be determined. It is likely, however, that antibody-induced 
clonal proliferation of lymphocytes expressing a  given  clonotype may greatly 
depend on the frequency of their precursors in the original T  cell population, as 
well as on the presence of IL-2-producing cells among such Ti + precursors. It is 
also likely that the stimulatory capability of anticlonotypic mAb is contingent on 
the affinity and class (or the subclass) of the antibody itself and on the epitope 
recognized; it should be noted, however, that JTii andJTi2 have been shown to 
recognize different epitopes of theJA3 T cell receptor (4). Our results also imply 
that (at least some) anticlonotypic antibodies can replace antigen, as a triggering 
signal, in normal resting T  cells. This observation appears of interest since, up 
to now, anti-Ti antibodies have been shown to mimic the effect of specific antigen 
only at the level of the corresponding Ti + T  cell clones, which are represented 
always by activated cells (3,  4).  Another remarkable observation is that a given MORETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT  1397 
FIGURE 3.  Clonotype-specific anti-JTi mAb immunoprecipitate similar molecules from JA3 
cells or fi'om PB lymphocyte populations stimulated with anti-JTi antibody. (A) Analysis of 
ami-JTi-reactive molecules by SDS-PAGE under reducing conditions. (Lane a) OKT6 mAb 
nonreactive with activated mature T  cells; (lane b) anti-JTi2 mAb-reactive molecules precipi- 
tated from JA3; (lane c) anti-JTi2 mAb-reactive molecules precipitated from anti-JTi-stimu- 
lated  PB  lymphocytes.  (B)  Analysis of anti-JTi-reactive molecules  by  SDS-PAGE  under 
nonreducing conditions. (Lane a) Anti-JTi2 mAb-reactive molecules precipitated from JA3; 
(lane b) anti-JTi= mAb-reactive molecules precipitated from anti-JTi-stimulated PBL; (lane c) 
OKT6 mAb nonreactive with activated mature T  cells. 
anticlonotypic mAb can activate both T8 + and T4  + JTi  + precursor cells, indicat- 
ing  that  T  cells  belonging  to  different  subsets  can  use  the  same  clonotypic 
structure.  It remains  to be determined  how this finding relates to the fact that 
T4 + cells recognize antigen in association with major histocompatibility complex 
(MHC) class  II  molecules,  whereas T8 + cells recognize  antigens  in  association 
with MHC class I molecules (9). 
Summary 
Three  previously selected monoclonal  antibodies (mAb) directed against  the 
clonotypic  structure  of  a  variant  (termed  JA3)  of  the  interleukin  2  (IL-2)- 
producing Jurkat  leukemia cell line (anti-JTi~_3  mAb) were found to induce an 
adherent cell-dependent proliferation of peripheral blood T  cells in 20 different 
donors.  Unlike  the  early  cell  proliferation  induced  by anti-T3  mAb,  anti-JTi 
mAb-induced  proliferation  was detectable at  day 5-6  of culture  and  reached 
peak levels at day 7-9. Less than  1% JTi + cells were consistently detected in the 
starting peripheral  blood lymphocytes or in control cultures in which cells were 
stimulated with anti-T3, phytohemagglutinin,  or allogeneic cells. However, JTi + 
cells were found in increasing proportions after culture with anti-JTi  mAb and 
they were mostly represented by large blast cells expressing either the T4 or the 
T8  antigen,  together  with  typical activation  antigens  including  HLA-DR,  IL-2 
receptor,  and  4F2.  Immunoprecipitation  experiments and sodium dodecyl sul- 
fate-polyacrylamide gel electrophoresis showed that anti-JTi-reactive molecules 1398  MORETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
present on antibody-stimulated lymphocytes or on JA3 cells were similar,  disul- 
phide-linked heterodimeric structures. 
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